Targeting NK cell CLEC12B enhances cancer immunotherapy - PubMed
6 hours ago
- #NK cells
- #CLEC12B
- #Cancer immunotherapy
- NK cells are innate immune effectors but can be compromised in the tumor microenvironment.
- CLEC12B is identified as an inhibitory checkpoint that restricts NK cell-mediated antitumor immunity.
- High CLEC12B expression in tumor-infiltrating NK cells correlates with poor prognosis in hepatocellular carcinoma.
- Lipoprotein lipase is a functional ligand for CLEC12B, triggering inhibitory signaling that suppresses NK cell activation.
- A high-affinity nanobody was developed to disrupt the CLEC12B-lipoprotein lipase axis, revitalizing NK cell activity and suppressing tumor progression.
- The nanobody shows synergistic efficacy when combined with PD-1 blockade.
- CLEC12B is established as a promising therapeutic target for solid malignancies.